Director/PDMR Shareholding
Avast plc
(the "Company")
2 July 2019
Director/PDMR Shareholding
The Company received notification on 28 June 2019 from Vincent Steckler (CEO of the Company as at the day of the notification) of his donation for no consideration of 55,000 ordinary shares in the Company to the Magical Bridge Foundation.
Following the donation, Mr Steckler is interested in 31,274,910 ordinary shares in the Company (excluding awards or options under employee share schemes), representing 3.20% of the Company's issued share capital.
The Notification of Dealing Form provided in accordance with the requirements of the Market Abuse Regulation in relation to this transaction is set out below:
1 | Details of the person discharging managerial responsibilities / person closely associated | |||||||
a) | Name | VINCENT STECKLER | ||||||
2 | Reason for the notification | |||||||
a) | Position/status | EXECUTIVE DIRECTOR | ||||||
b) | Initial notification /Amendment | INITIAL NOTIFICATION | ||||||
3 | Details of the issuer | |||||||
a) | Name | Avast plc | ||||||
b) | LEI | 213800IR8G8LC2H4BO27 | ||||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||||
a) | Description of the financial instrument, type of instrument | ORDINARY SHARES OF GBP 0.10 EACH IN AVAST PLC (ISIN: GB00BDD85M81)
| ||||||
b) | Nature of the transaction | DONATION TO THE MAGICAL BRIDGE FOUNDATION | ||||||
c) | Price(s) and volume(s) |
| ||||||
d) | Aggregated information - Aggregated volume - Price |
| ||||||
e) | Date of the transaction | 27 June 2019 | ||||||
f) | Place of the transaction | LONDON STOCK EXCHANGE (XLON)
|
Alan Rassaby
Company secretary
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.